Expression of the ®broblast growth factor (FGF) axis was examined during prostate cancer progression in the autochthonous Transgenic Adenocarcinoma of Mouse Prostate (TRAMP) model, including TRAMP derived cell lines. Transcripts for FGF-7 and FGF-10 that are normally expressed by the stroma were detected in all samples, including the epithelial cell lines, suggesting that elaboration of these factors by the epithelium may be an essential event during transformation. Interestingly FGFR2iiib, the FGF-7 and FGF-10 receptor, was downregulated during tumor progression whereas a novel FGFR1iiic (F) inframe splice form was found to be expressed. These observations support the hypothesis that speci®c changes in FGF axis correlate with, and probably facilitate, tumor progression.
Introduction
In the prostate, the epithelial cells are dependent on androgen-responsive stromal cells for branching morphogenesis, differentiation and survival. 1, 2 However, the molecular mechanisms whereby androgens in¯uence the mesenchyme to induce and direct epithelial differentiation and function remain relatively uncharacterized. Recently members of the heparin-binding ®broblast growth factor (FGF) family, namely FGF-7 and FGF-10, have been implicated as andromedins, that is, mediators of androgen action. These ligands are produced by the stroma and their cognate receptor FGFR2iiib is localized to the epithelium 3±5 (Axel Thomson, personal communication). It has also been demonstrated in prostatic organ culture that exogenous FGF-7 can induce epithelial growth and branching morphogenesis in the absence of androgens while neutralizing antibodies to FGF-7 effectively block testosterone induced development. 6 Hence, FGF-7 and FGF-10 are ideal candidates to mediate androgen-dependent stromal-epithelial interactions.
It is generally accepted that during tumor progression the prostatic epithelium becomes independent from the associated stroma for survival. Therefore, we have postulated that changes in the temporal and spatial pattern of FGF expression is pivotal in tumor progression. This has been supported by observations in the rat Dunning tumor system, where the spatial pattern of FGF axis expression was altered following malignant transformation. In the Dunning system a`switch' was found to occur in the celltype speci®city of the FGF receptors, and a different pattern of FGF ligands was concurrently observed during tumor progression resulting in a loss of stromal responsiveness and dependence. 7 It has also been demonstrated that during human prostate cancer progression, expression of FGF-7 may`switch' from the stromal to epithelial compartment. 8 Hence, changes in the expression of the FGF axis have been implicated in the development both of clinical prostate cancer and in animal models. Due to the paucity of clinical specimens representing the earliest stages of prostate cancer, we have utilized the transgenic adenocarcinoma of mouse prostate (TRAMP) model to examine changes during prostate cancer progression in the speci®c members of the FGF axis implicated in stromal-epithelial interactions.
Materials and methods

Transgenic mice
TRAMP is a spontaneous autochthonous transgenic mouse model of prostate cancer. 9 In this model a minimal probasin promoter containing 426 bp of 5 0¯a nking sequence and 28 bp of 5 0 untranslated sequence of the rat probasin gene was used to target expression of simian virus 40 large T antigen (Tag) to the epithelium of the mouse prostate. The development and progression of prostatic cancer in the TRAMP model closely mimics the human disease. In the TRAMP model, prostatic disease progresses from mild to severe intraepithelial neoplasia, to focal adenocarcinoma that metastasizes to the lymph nodes, lungs, and occasionally to bone, kidney and adrenal glands. 10 In these experiments TRAMP mice, heterozygous for the PB-Tag transgene, were maintained in a pure C57BL/6 background. Female TRAMP mice were bred to nontransgenic FVB male mice (Harlan Sprague Dawley, Inc., Indianapolis, IN) to obtain [C57BL/6xFVB]F1 male TRAMP mice. Transgenic mice were identi®ed by PCR-based screening on tail DNA as previously described.
9,10 TRAMP mice were randomly assigned to cohorts and sacri®ced at 12, 18, and 24 weeks of age.
Cell lines and culture conditions
The TRAMP-C1, TRAMP-C2 and TRAMP-C3 cell lines were derived from a primary tumor of a 32 week male C57BL/6 mouse as previously described. 11 Clonal cell lines of the tumorigenic TRAMP-C1 and TRAMP-C2 cell lines were established by three rounds of limiting clonal dilution passage. Culture conditions for the cell lines were as reported previously.
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RNA isolation and analysis
Total RNA was isolated from cell lines using Trizol (Life Technologies, Grand Island, NY) according to the manufacturer's recommendations. Total RNA was isolated from the prostate and tumor tissue by CsCl centrifugation as previously reported. 12 The reverse transcription-polymerase chain reaction (RT-PCR) was performed with 1 mg of total RNA essentially as described. 13 Ribosomal L-19 was used as a control for each reaction. C FGFR1iiib and FGFR1iiic. PCR products were fractionated on an 2% high resolution agarose gel (Amresco, Solon, OH). FGFR products were transferred to Hybond membrane (Amersham, Arlington Heights, IL) and hybridized with 32 P-labeled oligonucleotides that anneal within the ampli®ed region as previously described. 11 The following oligonucleotides were used as probes: FGFR1 internal: ACT CTC TGC ACT GCC AGG CCA G; FGFR2 internal: GAG CAT CGC ATT GGA GGC TAT AAG; FGFR3 internal: GTG GAG CTG AGC TGC CAT CCT C; and FGFR4 internal: CTA GCC CCA ATC CTG GAG CAG C.
Sequence analysis of FGFR1 variants
Variant forms of FGFR1iiib and FGFR1iiic were subcloned by standard methods. Brie¯y, ampli®ed products were fractionated on an agarose gel, excised and recovered by QIAquick Gel Extraction Kit according to manufacturer's recommendation (QIAGEN Inc., Valencia, CA). cDNA was ligated into EcoRV digested t-tailed pBluescript SKII (Stratagene) and colonies containing insert were identi®ed by blue/white selection. Inserts were isolated by QIAGEN Plasmid Maxi Kit (QIAGEN Inc., Valencia, CA) and DNA sequence determined (Molecular Genetics Core Facility, University of Texas-Houston Medical School). Sequences were aligned against GenBank 
Results
We have used the sensitive method of reverse transcription-polymerase chain reaction (RT-PCR) in order to comprehensively analyze the changes in the speci®c members of the FGF axis implicated in stromal-epithelial signaling during prostate cancer progression in an autochthonous model system. Here we report on the expression of these ligands and receptors in primary prostate tissues obtained from TRAMP mice at 12, 18 and 24 weeks of age that represent different stages of tumor progression, as well as in TRAMP derived parental and clonal cell lines.
For the purpose of this study primary tumors from TRAMP mice were categorized by weight into small and large cohorts based on urogenital tract wet weight (UG). Mice with small tumors had a UG weight less than 3 gm and were representative of early stage disease, while mice with large tumors had a signi®cantly greater tumor volume (greater than 3 gm) and were representative of late stage disease. The TRAMP-C1 (C1), TRAMP-C2 (C2) and TRAMP-C3 (C3) cell lines were isolated as mixed cell populations and when grafted s.c. into a male C57BL/6 host the C1 and C2 lines were found to be tumorigenic while the C3 line was non-tumorigenic. 11 In order to analyze expression of the FGF axis in pure cell populations, clonal cell lines were also established from C1 and C2 by three rounds of dilutional cloning. None of the cell lines were found to express SV40 T antigen as determined by RT-PCR and all were cytokeratin positive, 11 and data not shown.
Androgen receptor (AR) and probasin (PB) are both expressed by terminally differentiated androgen-responsive prostatic epithelial cells and were used as markers of normal prostate epithelial differentiation. 16, 17 As shown in Figure 1 , expression of AR mRNA was demonstrated in all samples analyzed. In contrast, probasin mRNA was not detected in two of the large TRAMP tumors (samples 9 and 11) indicating that these tumors, despite expressing AR, were poorly differentiated. Consistent with previous observations, expression of probasin mRNA was not detected in the cell lines grown in vitro. However, when grafted s.c. into¯anks of C57BL/6 mice approximately 1/3 of C1 and C2 tumors express probasin suggesting that in addition to AR, either other serum factors or higher-order cell-cell interactions are required for probasin expression.
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As shown in Figure 2 , FGF-1 and FGF-2 mRNA were detected in the normal prostate samples and in all but one tumor sample (sample 9). In contrast, a weak signal for FGF-1 mRNA was detected after 30 cycles of ampli®ca-tion in the cell lines. The expression of FGF-7 mRNA and FGF-10 mRNA was detectable in the complete sample set. This was surprising especially in the large tumors that were comprised primarily of epithelial cells and in the epithelial cell lines, since FGF-7 and FGF-10 in the prostate are normally expressed exclusively by the stroma 4, 5 (Axel Thomson, personal communication). These data demonstrate that FGF-7 and FGF-10 can be expressed by the epithelial cells during prostatic cancer progression, and support the hypothesis that a transition from an Wild type (wt) sequence is based on GenBank FGFR1 sequence U22324. 13 The primers used for ampli®cation are underlined. The full length sequence is the FGFR1iiica isoform, while the open box identi®es the sequence spliced out in the FGFR1iiicb isoform and black box identi®es the sequence spliced out in the FGFR1iiicF isoform. The circle identi®es the acid box.
epithelial to a more mesenchymal-like phenotype can occur early in neoplastic transformation and suggests that this may impart growth advantage to these cells.
Multiple forms of FGFR1, FGFR2 and FGFR3 arise from the alternative splicing of exons iiib/iiic. These exons determine ligand speci®city. Hence mRNA expression patterns of the iiib and iiic splice forms of FGFR1-3 were examined using splice-speci®c primers. As shown in Figure 3 , two species of FGFR1iiib (a and b) were identi®ed and con®rmed by Southern blotting and hybridization with an 32 P-labeled internal oligonucleotide. Sequence analysis revealed that FGFR1iiiba encoded the three Ig-loop structure, while FGFR1iiibb encoded the two Ig-loop structure.
As shown in Figure 3 , three species of FGFR1iiic (a, b and F) were identi®ed in all samples and con®rmed by hybridization with a 32 P-labeled internal oligonucleotide. (FGFR1iiic was detected in sample 4 in a subsequent RT-PCR analysis not shown). Sequence analysis (Figure 4a ) indicated that FGFR1iiica encoded the three Ig-loop structure while FGFR1iiicb encoded the two Ig-loop structure. Although the a and b forms had previously been described, FGFR1iiicF represents a novel splice form of the FGFR1 gene. Curiously, FGFR1iiicF lacks most of the intervening sequence between loop II and loop III (bp 751±873), and these splice sites have not been previously reported. 18, 19 However, the FGFR1iiicF is an inframe fusion that still contains cysteine residues at positions 249 and 296 (Figure 4b ) suggesting it may be capable of forming an Ig loop. It is interesting to note that FGFR1iiicF was more predominant in late stage tumors (samples 10, 11 and 12) and the cell lines.
Expression of FGFR2iiib mRNA was detected in normal prostate, the small tumors and some large tumors, however, FGFR2iiib was not a major transcript in two of the large tumors (samples 8 and 9) and all the cell lines (Figure 3) . These results were con®rmed using a second set of FGFR2iiib-speci®c primers (data not shown) and by hybridization with a 32 P-labeled internal oligonucleotide. FGFR2iiic mRNA was detected in all of the samples analyzed, however FGFR2iiic was not a major transcript in sample 9 and the non-tumorigenic cell line, C3. The expression of FGFR3iiib mRNA was variable. Late stage tumor samples 10, 11 and 12 had the highest relative levels of FGFR3iiib mRNA expression, while expression of FGFR3iiib mRNA in samples 4, 7, 8, 9 and the cell lines was not detected. Expression of FGFR3iiic mRNA was detected at low albeit variable levels in the sample set. It was not surprising that expression of FGFR4 mRNA was not detected in any of the samples analyzed as this receptor has not been previously implicated in prostate growth, development or cancer.
Discussion
The FGF axis is comprised of multiple genes encoding the FGF ligands with FGF-18 being the newest member identi®ed 20 and four genes encoding transmembrane tyrosine kinase receptors (FGFR1-FGFR4) . 19 The FGF ligand interacts with the extracellular domain of the cognate receptor resulting in receptor dimerization, transphosphorylation of the receptor intracellular tyrosine kinase domain and subsequent signal transduction. 19, 21 Three of four receptors, FGFR1, FGFR2 and FGFR3 are alternatively spliced to give rise to molecules having differing af®nities for the various FGF ligands. In the case of FGFR2, for example, when exon iiib is present the resulting receptor (FGFR2iiib) binds FGF-1 and FGF-7 but does not bind FGF-2. However, if exon iiic is present, the receptor (FGFR2iiic) binds FGF-1 and FGF-2, but not FGF-7. In the case of FGFR2, the alternative splicing of exon iiib or iiic is believed to be mutually exclusive for a given cell type. 22 The spatial pattern of FGF-7, FGF-10 and FGFR2iiib expression in the prostate make these molecules ideal candidates to act as mediators of stromalepithelial signaling, and hence were the focus of this study.
It is generally accepted that during tumor progression the prostatic epithelium must become independent from its associated stroma for its survival. Given the tight association between FGF expression and prostate growth and development it is hypothesized that changes in the FGF axis could play a pivotal role in tumor progression. Our data from the TRAMP model indicate that FGF-7 and FGF-10 are expressed by the epithelial cells during tumor progression, raising the possibility the epithelium escapes stromal dependence and growth regulation by expressing these otherwise stromal factors. Therefore, FGF-7 and FGF-10 switch from acting as paracrine stromal factors to autocrine epithelial factors.
It is interesting to note that expression of FGF-7 mRNA and FGF-10 mRNA were readily detected in the larger and more poorly differentiated TRAMP tumors, comprised primarily of epithelial cells, as well as in the epithelial TRAMP cell lines. These data are in general agreement with previously reported studies on clinical prostate cancer where in situ hybridization analysis demonstrated that FGF-7 mRNA was detected in low and high grade prostate carcinomas and that FGF-7 expression was observed to increase with Gleason grade and metastasis. 8 Since the expression of stromal FGFs was detected in all of the TRAMP epithelial cell lines, even in TRAMP-C3 that is non-tumorigenic, this switch may be an early or necessary event in prostate cancer progression and may play a pivotal role in the ability of a cell to acquire stromal independence.
Since FGF-7 and FGF-10 are believed to mediate androgen signals from the stroma to the epithelium during prostate development and growth, it is tempting to speculate that epithelial expression of FGF-7 and FGF-10 may also be contributing events in the acquisition of androgen independence. Studies to test the hypothesis that expression of FGF-7 by the epithelium is an early and predisposing event in prostate cancer progression and androgen-independence are currently being investigated using transgenic mice that ectopically express FGF-7 in the epithelium (manuscript in preparation). In reciprocal studies, FGF-7 7/7 mice that have been generated by homologous recombination and are reported to have normal prostatic development 23 are being crossed to TRAMP mice to further assess the consequence of abrogated FGF-7 signaling in prostate tumor progression.
While ligand switching is one potential route to stromal independence during tumor progression, another complementary mechanism is through receptor switching. Our data from the TRAMP model supports such a hypothesis. For example, FGFR1 is normally expressed in prostate stroma and was detected in all of the tumor samples and the epithelial TRAMP cell lines. This strongly suggests that during tumor progression the epithelium acquires the ability to express an FGFR that is normally found in the stroma and may provide tumor cells with a growth advantage. In fact, expression of FGFR1 kinase domain has been demonstrated to accelerate progression of premalignant prostate epithelial cells toward the malignant phenotype in the Dunning tumor model. 7 We have identi®ed a novel splice form of FGFR1iiic (F) whose expression appears to correlate with tumor progression. This receptor has a deletion of the sequence between Ig-loop II and III. Despite the fact that the splice donor and acceptor sites had not been previously identi®ed this splice creates an inframe fusion that still contains cysteine residues 249 and 246 and may still be capable of forming an Ig loop. However, the deleted region has been identi®ed as an important structural component required for receptor dimerization. 19 Therefore, it will be interesting to characterize the ability of FGFR1iiicF to bind ligand, discriminate between ligands, to form homo-or heterodimeres and to transduce signal in a ligand dependent or independent fashion. The pattern of FGFR1iiicF mRNA expression raises the intriguing possibility that FGF-7 and FGF-10 may be able to signal through FGFR1iiicF.
It is interesting to note that FGF-1, a ligand for FGFR2iiib, and the FGFR2iiib receptor itself appear to be coordinately loss during tumor progression and in the cell lines. The loss of FGFR2iiib expression has also been demonstrated in tumor progression in the Dunning tumor system. 7, 24 As previously reported, FGFR2 switches from the iiib isoform, that binds FGF-1, FGF-7 and FGF-10, to the alternatively spliced iiic isoform, that binds FGF-1 and FGF-2. These changes in the FGF axis have been associated with progression to a more metastatic phenotype. 24 Conversely, studies in the Dunning tumor system have also demonstrated that introducing FGFR2iiib kinase to a highly malignant prostate tumor cell lines that expresses only FGFR1 has a growth inhibitory effect. 7, 25 Together these observations support the hypothesis that signaling through FGFR1 is consistent with growth and cancer progression, whereas signaling through FGFR2 is consistent with differentiation. We have recently generated transgenic mice that express a dominant negative FGFR2iiib in the prostatic epithelium to investigate the hypothesis that loss of FGFR2iiib signaling accelerates prostate cancer progression in TRAMP (manuscript in preparation).
Conclusion
During progression of prostate cancer in an autochthonous model we have demonstrated that expression of FGF-7 and FGF-10 mRNA switch from the stromal to epithelial compartment while expression of their cognate FGFR2iiib receptor is lost and expression of a novel FGFR1iiic F is gained ( Figure 5 ). Our data support the hypothesis that during prostate progression speci®c changes occur in the expression of the members of the FGF axis implicated in stromal-epithelial signaling. Furthermore, it is clear that changes in the FGF axis may play a pivotal and early role in the progression of prostate cancer. It now remains to be determined at the molecular level if these changes provide growth advantage and to de®ne possible roles of the newly identi®ed FGFR1iiic F during tumor progression. Figure 5 Schematic representation of the changes in the FGF axis during prostate cancer progression. In the normal prostate the stroma expresses FGF-7 and FGF-10 and the epithelium expresses the cognate receptor FGFR2iiib. In prostatic adenocarcinoma the epithelium becomes independent from associated stroma and begins to express FGF-7 and FGF-10. Concomitantly, in the epithelium FGFR2iiib expression is lost and FGFR1iiic expression is gained. Most notably the novel FGFR1iiic F isoform is expressed in advanced disease.
